Tbx-1400 (DrugBank: -)
1 diseaseID | Disease name (Link within this page) | Number of trials |
---|---|---|
65 | Primary immunodeficiency | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02860559 (ClinicalTrials.gov) | August 2021 | 26/7/2016 | Safety and Early Efficacy Study of TBX-1400 in Patients With Severe Combined Immunodeficiency | Safety and Early Efficacy Study of TBX-1400 in Patients With Severe Combined Immunodeficiency | Severe Combined Immunodeficiency | Biological: TBX-1400 | Taiga Biotechnologies, Inc. | NULL | Not yet recruiting | 1 Month | 4 Years | All | 8 | Phase 1 | Israel |